Stabile Laura P, Siegfried Jill M
Department of Pharmacology, University of Pittsburgh, Hillman Cancer Center, UPCI Research Pavilion, Suite 2.18, Pittsburgh, PA 15213-1863, USA.
Curr Oncol Rep. 2004 Jul;6(4):259-67. doi: 10.1007/s11912-004-0033-2.
Lung cancer is the leading cause of death from neoplasia in men and women in the United States. Some studies suggest that women are more susceptible than men to tobacco-induced carcinogenesis and may show higher risk than men for lung cancer development from smoking. More recently, increasing biochemical and genetic data have supported this male-female difference in response to tobacco. Estrogens may be involved in lung carcinogenesis, and estrogen receptors (ERs), mainly ERb, are present and functional in normal lung and tumor cell lines and tissues. Estrogen can directly stimulate the transcription of estrogen-responsive genes in the nucleus of lung cells, and it can also transactivate growth factor signaling pathways, in particular the epidermal growth factor pathway. Lung cancer patients currently have few effective therapeutic options. An understanding of these new developments in estrogen signaling and cross-talk pathways may pave the way for innovative combinatorial approaches for treatment of lung cancer and possibly chemoprevention.
肺癌是美国男性和女性肿瘤相关死亡的主要原因。一些研究表明,女性比男性更容易受到烟草诱导的致癌作用影响,并且在吸烟导致肺癌发生方面可能比男性表现出更高的风险。最近,越来越多的生化和遗传数据支持了这种在对烟草反应上的男女差异。雌激素可能参与肺癌发生过程,并且雌激素受体(ERs),主要是ERb,存在于正常肺组织、肿瘤细胞系和组织中并发挥功能。雌激素可以直接刺激肺细胞核中雌激素反应基因的转录,还可以激活生长因子信号通路,特别是表皮生长因子通路。目前肺癌患者的有效治疗选择很少。了解雌激素信号和相互作用通路的这些新进展可能为肺癌治疗和化学预防的创新联合方法铺平道路。